BlossomHill’s BH‑30643: Fast‑Track Oral EGFR Inhibitor Set to Break Ground on C797S‑Resistant NSCLC at WCLC 2026
BlossomHill unveils SOLARA data for BH‑30643, an oral macrocyclic EGFR TKI tackling C797S resistance in EGFR‑mutant NSCLC—fast‑track status, global trial, and market impact.
3 minutes to read